Welcome to our dedicated page for Globalink Investment SEC filings (Ticker: GLLIU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Globalink Investment's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Globalink Investment's regulatory disclosures and financial reporting.
Silexion Therapeutics Corp (SLXN) has filed an amended Form 8-K to clarify timing details surrounding its Nasdaq listing status.
The Nasdaq hearings panel has granted the company continued listing but will transfer the ordinary shares and warrants from the Nasdaq Global Market to the Nasdaq Capital Market as soon as practicable. While the original filing stated the move could occur on 8 July 2025, the amendment notes the exact date remains uncertain.
Silexion also warns it may become non-compliant with Nasdaq Listing Rule 5550(a)(2) (minimum $1.00 bid price) if its shares close below that threshold for 30 straight trading days. Management intends to cure any deficiency through a 1-for-15 reverse share split, subject to shareholder approval at the reconvened AGM on 14 July 2025. After approval, a mandatory 10-day Nasdaq notice period would push the split to roughly 25 July 2025, with compliance only achieved after the stock trades above $1.00 for 10 consecutive days—placing the earliest compliance window in early-to-mid August 2025.
The company cautions that there is no assurance shareholders will approve the split or that the post-split price will meet Nasdaq requirements, leaving a continued risk of delisting.
Globalink Investment Inc. (NASDAQ: GLLIU) filed an 8-K on 3 July 2025 announcing its 25th deadline extension for completing a de-SPAC transaction. The company deposited $0.15 per public share, or $10,890.15, into its trust account, pushing the business-combination deadline from 9 July 2025 to 9 August 2025.
This is the second of up to six one-month extensions allowed under the SPAC’s amended charter. The cost of each extension is borne by the sponsor and preserves the trust’s cash per share for investors. No target has yet been announced, leaving investors reliant on continued extensions or a potential liquidation if a deal is not secured by the final permitted date.
Key details
- Form type: 8-K, Item 2.03 (Direct Financial Obligation).
- Extension payment: $10,890.15 ($0.15 per share).
- New termination date: 9 Aug 2025.
- Total extensions since IPO (Dec 2021): 25 months.
- Exhibit 99.1: Press release describing the extension.
Investor take-away: The additional month preserves the SPAC option value but underscores management’s prolonged search for a target. Each successive short-term extension increases uncertainty over eventual deal quality and timing.
FAQ
What is the current stock price of Globalink Investment (GLLIU)?
